Registration of APIs CMC information required for an IND
IND and NDA support Drug master files (DMF) filing
M.F/Formula | C₂₁₈H₃₅₅N₆₅O₅₂S |
M.W/Mr. | 4750.69 |
Sequence | H-Asn(4-aminobutyl)-Ala-Gln(4-aminobutyl)-Phe-Arg-His-Asn(4-aminobutyl)-Ser-Gly-Tyr-Gln(4-aminobutyl)-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Gln(4-aminobutyl)-Asn(4-aminobutyl)-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH triflu |
Source# | Synthetic |
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
3. Implications of ligand-receptor binding kinetics on GLP-1R signalling
Required fields are marked with *
×Required fields are marked with *
×If you have any peptide synthesis requirement in mind, please do not hesitate to contact us. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com